标题：左氧氟沙星治疗耐多药肺结核病近期临床疗效观察

      作者：朱琼香
    （恩施州中心医院感染科，湖北 恩施 445000）

      卷次： 2014年25卷24期

      【摘要】 目的 探讨左氧氟沙星治疗耐多药肺结核病(MDR-PTB)患者的近期临床疗效。方法 将80例确
诊为MDR-PTB患者随机分组为对照组和治疗组。其中，对照组40例采用3SEL2DZ/15EL2D方案治疗，治疗组
40例采用3CmVL2DZ/15VL2D方案治疗。结果 疗程结束时，治疗组的临床症疗效总有效率为85.0%，对照组
的总有效率为62.5%，组间比较差异有统计学意义(P<0.05)，治疗组的临床疗效优于对照组；在治疗3个月和疗程结
束时，治疗组的痰菌阴转率分别为67.5%和87.5%，对照组的痰菌阴转率分别为45.0%和67.5%，组间比较差异有统
计学意义(P<0.05)，治疗组的痰菌阴转率大于对照组；在疗程结束时，治疗组的病灶吸收和空洞闭合好转率分别为
92.5%和88.9%，对照组的病灶吸收和空洞闭合好转率分别为72.5%和68.6%，组间比较差异有统计学意义(P<0.05)，
治疗组的病灶吸收和空洞闭合改善更加明显。在治疗期间，治疗组的不良反应发生率低于对照组，但是组间比较差
异无统计学意义(P>0.05)。结论 左氧氟沙星治疗MDR-PTB患者的临床疗效好，值得临床推广应用。

      【关键词】 肺结核；耐多药；左氧氟沙星；疗效

      【中图分类号】 R521 【文献标识码】 A 【文章编号】 1003—6350（2014）24—3627—03


Short-term clinical effect of levofloxacin in the treatment of patients with multidrug-resistant pulmonary
tuberculosis.
ZHU Qiong-xiang, Department of Infections Diseases, the Central Hospital of Enshi Prefecture, Enshi
445000, Hubei, CHINA

【Abstract】 Objective To investigate the short-term clinical effect of levofloxacin in the treatment of patients
with multidrug resistant pulmonary tuberculosis (MDR-PTB). Methods Eighty patients with MDR-PTB were ran-
domly divided into the control group and the treatment group, each with 40 cases. Therapy of 3SEL2DZ/15EL2D and
3CmVL2DZ/15VL2D were adopted in the control group and the treatment group, respectively. Results At the end of
treatment process, the total effective rate of the treatment group was 85.0%, significantly higher than 62.5% in the con-
trol group (P<0.05). The clinical effect of the treatment group was better than that of the control group. After 3 months
and 18 months of treatment, the negative conversion rate of acid-fast bacilli sputum smear was 67.5% and 87.5% in
treatment group, 45.0% and 67.5% in control group, respectively, with significant difference between the two groups
(P<0.05). At the end of treatment process, the improvement rate of clinical symptoms of lesions absorption and cavity
closure was 92.5% and 88.9% in treatment group, 72.5% and 68.6% in the control group, respectively, with statistical-
ly significant difference between the two groups (P<0.05). In the treatment process, the incidence rate of adverse reac-
tions in treatment group was lower than that of control group, but there was no statistically significant difference (P>
0.05). Conclusion There is significant clinical effect of levofloxacin in treatment of patients with MDR-PTB. The
therapy is worthy of clinical popularization and application.